Medicenna Will Present MDNA11 Data in Phoenix
Medicenna Therapeutics will share trial data on MDNA11 at the SITC 2026 Annual Meeting on November 7.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you trust the information provided by pharmaceutical companies regarding new clinical trial results?
Medicenna Therapeutics is set to present Phase 1/2 clinical trial data for its investigational drug MDNA11 on November 7, 2026. The presentation will take place in Phoenix at the Society for Immunotherapy of Cancer annual meeting.
Why it matters
The presentation highlights ongoing research into cytokine therapies for patients battling advanced metastatic cancers that have proven resistant to standard immunotherapy.
The Society for Immunotherapy of Cancer selected abstract 517 as one of its top 150 submissions. The ABILITY-1 clinical trial evaluates the drug in patients with metastatic gastrointestinal, endometrial, and melanoma cancers.
The players
Medicenna Therapeutics
A developer of cytokine therapies for cancer and autoimmune disease headquartered in Toronto with offices in Houston.
Society for Immunotherapy of Cancer
A professional medical society that organizes the annual meeting scheduled to take place at the Phoenix Convention Center.
The details
Researchers will deliver an oral presentation regarding MDNA11's performance as a monotherapy and in combination with pembrolizumab. The study utilizes expansion cohorts to evaluate the safety and clinical activity of the drug within biomarker-enriched malignancy populations.
Timeline
October 5, 2026: Medicenna announced the upcoming data presentation.
November 7, 2026: Medicenna presents study data at the SITC meeting.
The Big Picture
The clinical progression of MDNA11 reflects the established development trajectory set by the FDA Fast Track designation process for oncology therapies. This study follows the pattern established by Medicenna's previous program, bizaxofusp, which successfully utilized this regulatory pathway.
The study offers potential new treatment avenues for patients with advanced cancers that have become resistant to current immunotherapy options. Attendees and patients can monitor the trial results to see how these therapies may eventually shift standard oncology treatment protocols.
The takeaway
Advancements in cytokine therapy research continue to focus on hard-to-treat malignancies that do not respond to traditional immune checkpoint inhibitors. Patients and caregivers should consult with oncologists about how emerging clinical trial data might inform future care decisions.
Further reading
Learn more about the latest research in the field on the Cancer page.
Live Poll
Do you trust the information provided by pharmaceutical companies regarding new clinical trial results?
